Research
Cellular
GLP-1 agonists positively affect multiple obesity-related complications.
GLP-1 agonists can be used to manage various obesity-related health issues.
StrongSupportsmedium confidence
Sus efectos sobre las alteraciones en la regulación de la ingesta, disfunción adipocitaria, resistencia a la insulina, producción de adipoquinas, inflamación, disfunción endotelial, metabolismo lipídico y estrés oxidativo posibilitan el control de numerosas complicaciones como la diabetes, la enfermedad hepática metabólica, la insuficiencia cardiaca y la arteriosclerosis.
Why this rating
The claim is supported by a comprehensive list of effects mentioned in the abstract.
Source
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Javier Salvador · Medicina Clínica · 2025
DOI 10.1016/j.medcli.2025.107035
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →